Plain-English translation of NCT07528066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial examines how well robot-assisted thoracoscopic surgery (a minimally invasive surgical technique) works for patients with stage IIB-III non-small cell lung cancer who have received neoadjuvant chemo-immunotherapy beforehand. The study will track whether the combination of PD-1/PD-L1 inhibitor plus platinum chemotherapy followed by surgery improves surgical outcomes and whether the cancer's response to this medication affects how well surgery works.
Advanced lung cancer is typically difficult to treat, and doctors want to understand whether combining chemotherapy with immunotherapy before surgery helps shrink tumors and improve the safety and effectiveness of robot-assisted surgery in these patients.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy combined with immunotherapy as planned with your medical team. Between 2–6 weeks after finishing this medication, you would have imaging scans to see how well the treatment worked. You would then undergo robot-assisted lung surgery 2–10 weeks after your last dose of medication. After surgery, you would return for follow-up appointments over the next 90 days so researchers can track your recovery and surgical outcomes.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China